|
For Immediate Release
October 18, 2001
Washington, DC - The Aspirin Foundation of America
(AFA) today objected to press reports of a recent study
from the University of Colorado Health Sciences Center
in Denver on acetaminophen toxicity. The study, published
in the Archives of Internal Medicine, was reported as
showing that the maximum daily dose of acetaminophen
is not associated with liver toxicity. However, in a
press release announcing the results of the study, which
was sponsored by McNeil Consumer Healthcare (the maker
of Tylenol), the authors of the study converted the
announcement into an attack on the safety of products
that compete with acetaminophen, like aspirin and other
nonsteroidal anti-inflammatory drugs.
Dr. Thomas Bryant, president of the AFA said, "It is
unfortunate that the authors would use this limited
study to mount an unfounded attack on competing products."
He pointed out that the study only measured the liver
effects of using the maximum dosage of acetaminophen
for a two-day period, not the maximum dosage of 10 days,
as indicated on Tylenol labels, and that the study did
not address the side effects of competing products.
"The researchers cannot use their research as the basis
for any comparative claims about competing products,"
Dr. Bryant said. "There is nothing in this study which
supports comparative claims against aspirin or NSAIDs."
###
Contact:
Caroline Perrin
807 National Press Building, Washington, DC 20036
Phone: 800-432-3247 Fax: 202/737-8406
info@aspirin.org
|
